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ABSTRACT 
 
 Nanoparticles with pH-sensitive behavior may enhance the success of chemotherapy in 
many cancers by efficient intracellular drug delivery. Here, we investigated the effect of a 
bioactive surfactant with pH-sensitive properties on the antitumor activity and intracellular 
behavior of methotrexate-loaded chitosan nanoparticles (MTX-CS-NPs). NPs were prepared 
using a modified ionotropic complexation process, in which was included the surfactant 
derived from Nα,Nε-dioctanoyl lysine with an inorganic lithium counterion. The pH-sensitive 
behavior of NPs allowed accelerated release of MTX in an acidic medium, as well as 
membrane-lytic pH-dependent activity, which facilitated the cytosolic delivery of endocytosed 
materials. Moreover, our results clearly proved that MTX-CS-NPs were more active against 
the tumor HeLa and MCF-7 cell lines than the free drug. The feasibilty of using NPs to target 
acidic tumor extracellular pH was also shown, as cytotoxicity against cancer cells was greater 
in a mildly acidic environment. Finally, the combined physicochemical and pH-sensitive 
properties of NPs generally allowed the entrapped drug to induce greater cell cycle arrest and 
apoptotic effects. Therefore, our overall results suggest that pH-sensitive MTX-CS-NPs could 
be potentially useful as a carrier system for tumor and intracellular drug delivery in cancer 
therapy. 
  
Keywords: chitosan nanoparticles; methotrexate; lysine-based surfactant; intracellular drug 
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1. Introduction 
 Chitosan (CS) is a naturally occurring polymer that has been attracting increasing 
attention in pharmaceutical and biomedical applications because of its biocompatibility, 
biodegradability, non-toxicity, cationic properties and bioadhesive characteristics [1-3]. CS 
nanoparticles (NPs) have been investigated as a promising colloidal drug carrier for targeted 
delivery to specific sites, as well as for gene and vaccine delivery, and cancer therapy [3-5]. 
The ionotropic gelation technique is one of the most widely used of a variety of methods to 
prepare CS-NPs [1,2,6,7]. This procedure is based on reversible crosslinking by electrostatic 
interaction (between protonized –NH3+ and an anion such as tripolyphosphate), instead of 
chemical crosslinking. It avoids the potential toxicity of reagents and the possibility of 
damaging the drugs, especially with biological agents [2,8]. 
 Methotrexate (MTX) acts as an antagonist of folic acid, which is necessary for DNA 
synthesis, and has a therapeutic effect on many types of cancer cells that overexpress folate 
receptors on their surfaces [9]. MTX is currently widely used as a major chemotherapeutic 
agent for human malignancies such as acute lymphoblastic leukemia, malignant lymphoma, 
osteosarcoma, breast cancer and head and neck cancer [10]. However, its clinical efficacy is 
often compromised by the acquisition of resistance in cancer cells, due to cellular efflux of the 
molecule [11]. In this context, the encapsulation of antitumor drugs in nanoparticulated 
systems like polymeric NPs, which retain a higher drug concentration within the cell, might 
overcome the shortcomings associated with conventional drug delivery strategies [12]. MTX-
loaded CS-based NPs have been developed using especially modified forms of chitosan, to 
improve controlled drug delivery to tumors [5,13]. A delivery system based on covalently 
conjugated CS-MTX has also been described, but has the drawback of using a cross-linked 
agent [14]. On the basis of the above studies and the need for an efficient drug carrier for 
cancer therapy, we decided to investigate the effect of a bioactive excipient with pH-sensitive 
properties on the antitumor activity and intracellular behavior of MTX-loaded CS-NPs. 
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 Lysosomal degradation of the chemotherapeutic agent is another major hurdle for 
successful cancer therapy. For nanocarriers to act efficiently, they must overcome intracellular 
barriers, such as endosomes, and release the drugs into the cytosol before they are ultimately 
trafficked to lysosomes [15]. Therefore, delivery devices with bioactive excipients have been 
developed, which selectively release drugs or genes into the cytoplasm by sensing low pH in 
endosomes [16]. Bioactive compounds that could be used in nanocarriers include amino acid-
based surfactants that have shown pH-responsive membrane-lytic activity [17-19]. The 
anionic amphiphile derived from Nα,Nε- dioctanoyl lysine with a lithium counterion (77KL) in 
particular showed pH-sensitive membrane-lytic behavior and low cytotoxicity [17]. This 
suggests that it may have a specific ability to destabilize the endosomal membrane in a mildly 
acidic environment without considerable toxic effects to the cell. Therefore, it was chosen as a 
bioactive excipient to be included in the pH-sensitive CS-NPs designed here as a promising 
carrier for the intracellular delivery of cancer drugs. In this context, CS-TPP-NPs modified by 
the cationic amphiphile cetyltrimethylammonium bromide are noteworthy, as they showed 
improved physicochemical properties, attributed to the inclusion of the surfactant [1]. The 
green fluorescent dye calcein and fluorescence microscopy analysis was used to monitor the 
capacity of the NPs to destabilize the endosomal membrane. MTX, a drug widely used in the 
treatment of cancer, was incorporated into CS-NPs, and the cytotoxic activity of the latter 
against tumor and non-tumor cell lines was assessed using in vitro toxicological assays.  
 
2. Experimental 
2.1. Chemicals and reagents 
Chitosan (CS) of medium molecular weight (deacetylation degree, 75-85%; viscosity, 
200-800 cP according to the manufacturer’s data sheet), pentasodium tripolyphosphate (TPP), 
methotrexate (MTX), acridine orange (AO), ethidium bromide (EB), propidium iodide, 
ribonuclease A (RNAse A), calcein, 2,5-diphenyl-3,-(4,5-dimethyl-2-thiazolyl) tetrazolium 
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bromide (MTT), neutral red (NR) dye and dimethyl sulfoxide (DMSO) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal 
bovine serum (FBS), phosphate buffered saline (PBS), L-glutamine solution (200 mM), 
trypsin-EDTA solution (170,000 U/l trypsin and 0.2 g/l EDTA) and penicillin-streptomycin 
solution (10,000 U/ml penicillin and 10 mg/ml streptomycin) were purchased from Lonza 
(Verviers, Belgium). The 75 cm2 flasks and 96-well plates were obtained from TPP 
(Trasadingen, Switzerland). All other reagents were of analytical grade. 
 
2.2. Surfactant included in the nanoparticles 
 An anionic amino acid-based surfactant derived from Nα, Nε-dioctanoyl lysine and 
with an inorganic lithium counterion (77KL) was included in the NP formulation (Table 1). 
This surfactant was synthesized by our group as previously described [20]. The choice of 
77KL as a bioactive excipient in the NP formulation was based on our previous studies, which 
showed its pH-sensitive membrane-disruptive activity, together with improved kinetics in the 
endosomal pH range and low cytotoxic potential [17,21]. 
 
2.3. Preparation of MTX nanoparticles 
 CS-NPs were prepared according to a modified version of the ionic gelation technique 
[6], which is based on the ionotropic complexation of CS with TPP anions. The surfactant 
77KL was included in the complexation process and the NPs were prepared with a selective 
CS:TPP:77KL ratio of 5:1:0.5 (w/w/w).  
 Unloaded CS NPs (unloaded-CS-NPs) were prepared by dropwise addition of a 
premixed TPP and 77KL solution (both at 0.1%, w/v, with a TPP:77KL ratio equal to 1:0.5, 
w/w) to CS (0.1%, w/v) previously dissolved in acetic acid solution (1%, v/v). The pH of the 
CS final solution was adjusted to 5.5 with 1 M NaOH [7]. The NPs were formed 
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spontaneously and the gelation process was carried out under constant magnetic stirring (500 
rpm) for 30 min at room temperature.  
 MTX-loaded CS NPs (MTX-CS-NPs) were prepared as follows: to a premixed TPP 
and 77KL solution (both at 0.1%, w/v, with a TPP:77KL ratio equal to 1:0.5, w/w), MTX was 
added to provide a final concentration of 0.07% (w/v) of the antitumor drug. MTX-NPs were 
prepared by dropwise addition of this premixed solution (TPP:77KL:MTX, with a final ratio 
of 1:0.5:1, w/w/w) to the previously prepared CS solution (0.1%, w/v). The NPs were formed 
at room temperature and dark conditions, under constant magnetic stirring (500 rpm) for 30 
min. The purification of the resulting NPs was carried out by exhaustive dialysis for 4 h, using 
a Spectra/Por® dialysis bag of 3,500 MWCO (Spectrum Medical Industries, CA, USA). 
 
2.4. Nanoparticle characterization 
 The mean hydrodynamic diameter and the polydispersity index (PDI) of the NPs were 
determined by dynamic light scattering (DLS) using a Malvern Zetasizer ZS (Malvern 
Instruments, Malvern, UK). Before measurement, the NPs were appropriately diluted in both 
distilled water and cell culture medium with 5% FBS, and the readings were taken at 25ºC 
immediately after preparation (t = 0 h) and after 24 h incubation at 37ºC (t = 24 h). Each 
measurement was performed using at least three sets of ten runs. 
 The zeta potential (ZP) values of the NPs were assessed by determining electrophoretic 
mobility with the Malvern Zetasizer ZS equipment. The measurements were also performed in 
both ultrapure water and cell culture medium with 5% FBS at 25ºC using at least three sets of 
20 runs. ZP is a measurement of the electric charge at the surface of the particles and indicates 
the physical stability of colloidal systems.  
 The morphology and size of the NPs were analyzed by transmission electron 
microscopy (TEM). A droplet (5 μl) of the NPs dispersed in distilled water was placed on a 
carbon-coated copper grid to form a thin liquid film, and the negative staining of samples was 
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obtained with a 2% (w/v) solution of uranyl acetate. The images were obtained with a Jeol 
JEM-1010 electron microscope (Jeol Ltd., Tokyo, Japan) operating at an acceleration voltage 
of 80 kV. 
 
2.5. Drug entrapment efficiency  
 The drug association efficiency was determined using the dialysis technique for 
separating the non-encapsulated drug from the NPs. Five milliliters of drug-loaded NPs was 
dropped into a dialysis bag (Spectra/Por®, 3,500 MWCO, Spectrum Medical Industries, CA, 
USA), the free drug was dialyzed for 60 min each time and the dialysis was completed when 
no drug was detectable in the recipient solution. The percentage of encapsulation efficiency 
(E%) of MTX in the NPs was measured using UV spectrophotometry (306 nm, UV-160A 
spectrophotometer, Shimadzu, Kyoto, Japan) and calculated as follows [22]:  
 
E% = 100 x (ND – D)/ ND                      (1) 
 
where ND and D are the drug concentrations before and after the dialysis, respectively. The 
E% value was the mean of three NP batches. 
          
2.6. In vitro release study 
 In vitro release assessments from MTX-loaded CS NPs were carried out for 24 h in 
phosphate buffered saline (PBS) at pH 7.4, 6.5 and 5.4. An aliquot of NPs (100 μg/ml) was 
placed in a dialysis bag (Spectra/Por®, 3,500 MWCO, Spectrum Medical Industries, CA, 
USA) and suspended in 15 ml of PBS at 37ºC under gentle magnetic stirring (100 rpm). At 
scheduled times, 2 ml of medium was withdrawn and replaced with an equal volume of fresh 
medium. The amount of MTX released was estimated by UV spectrophotometry (306 nm, 
UV-160A spectrophotometer, Shimadzu, Kyoto, Japan). All of the experimental procedure 
was performed in triplicate. The release of the free drug was also investigated in the same 
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way. The cumulative release percentage (CR%) of MTX at each time point was determined 
using the following equation:  
 
CR% = (Mt / Mi) x 100                                                                                                             (2) 
       
where Mi and Mt are the initial amount of drug encapsulated in the NPs and the amount of 
drug released at the time t, respectively. 
 
2.7. Cell cultures and treatments 
 The tumor cell lines HeLa (human epithelial cervical cancer) and MCF-7 (human 
breast cancer), and the non-tumor cell line HaCaT (spontaneously immortalized human 
keratinocytes) were grown in DMEM medium (4.5 g/l glucose) supplemented by 10% (v/v) 
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC, 5% CO2. 
These cells were routinely cultured in 75 cm2 culture flasks and were trypsinized using 
trypsin-EDTA when the cells reached approximately 80% confluence. All cell lines were 
obtained from Eucellbank (Universitat de Barcelona, Spain). 
 HeLa (5 x 104 cells/ml), MCF-7 (1 x 105 cells/ml) and HaCaT (1 x 105 cells/ml) cells 
were seeded into the 60 central wells of 96-well cell culture plates in 100 µl of complete 
culture medium. Cells were incubated for 24 h under 5% CO2 at 37ºC and the medium was 
then replaced with 100 µl of fresh medium supplemented by 5% (v/v) FBS containing the 
treatments. Unloaded-CS-NPs were assayed in the 3.9-500 μg/ml concentration range, 
whereas MTX-CS-NPs and free MTX were assessed in the 0.001-50 μg/ml concentration 
range. The concentration of unloaded-CS-NPs was based on their total composition, and the 
higher concentration range tested was attributed to their low cytotoxic potential. In contrast, 
the concentration of MTX-CS-NPs was based on the total amount of MTX encapsulated in the 
NPs, so that the results could be compared with those obtained using free MTX. Each 
concentration was tested in triplicate and control cells were exposed to medium with 5% (v/v) 
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FBS only. The cell lines were exposed for 4, 24 or 48 h to each treatment, and their viability 
was assessed by three different endpoints, as described below. 
 To assess the pH-dependent cytotoxicity of NPs and free MTX, we also exposed the 
cells to treatment at pH 6.6, which mimicks the acidic extracellular pH of tumors (pHe) [23]. 
DMEM 5% FBS was mixed with 1 M HEPES buffer pH 6.2 at a ratio of 5:1, and the resulting 
mixture, with an experimental pH of 6.6, was applied during the incubation of the NPs or free 
MTX (at the same concentration range as that described above) with HeLa or MCF-7 cells for 
4 or 24 h.  
 
2.8. Cytotoxicity assays – antitumor activity of MTX   
 The MTT assay is based on the protocol first described by Mossmann [24]. It is a 
measurement of cell metabolic activity, and correlates quite well with cell proliferation [25]. 
The assay was performed as previously described [26]. Cell viability was calculated as the 
percentage of tetrazolium salt reduction by viable cells in each sample and the values were 
normalized by the untreated cell control (cells with medium only). 
 The NRU assay is based on the protocol described by Borenfreund and Puerner [27], 
and reflects the functionality of the lysosomes and plasma membrane [28]. The assay was 
performed following the previously described protocol [26]. The effect of each treatment was 
calculated as the percentage of uptake of NR dye by lysosomes against the untreated cell 
control (cells with medium only). 
 LDH leakage was evaluated to determine the integrity of the plasma membrane using a 
commercially available kit (Takara Bio Inc, Otsu, Japan), in line with the instructions 
provided by the manufacturer. This assay quantifies cytotoxicity by measuring LDH released 
from dead or plasma membrane-damaged cells into the supernatant [29]. Absorbance was 
measured in a microplate reader (SunriseTM, Tecan, Switzerland) at 492 nm, with 620 nm set 
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as the reference wavelength. The results are expressed as a percentage of control, with 1% 
Triton-X used as a positive control. 
 To determine whether the NPs interacted with the viability assays, UV/Visible 
absorbance measurements were carried out [30]. Unloaded-CS-NPs at 500 μg/ml and MTX-
CS-NPs at 50 μg/ml were suspended in DMEM medium (without FBS and phenol red) 
containing MTT (0.5 mg/ml) or NR (50 μg/ml) dyes, and the occurrence of dye interference 
was assessed following the previously described procedure [26]. 
 
2.9. Apoptosis 
 NP-induced apoptosis in HeLa and MCF-7 cells was quantified using acridine 
orange/ethidium bromide (AO/EB) double staining, according to standard procedure [31] and 
using a fluorescence microscope. Briefly, cells were seeded (5 x 104 or 1 x 105 cells/ml, for 
HeLa and MCF-7, respectively) in 24-well plates and treated with 1, 10 or 50 μg/ml of MTX-
CS-NPs or free MTX. After 24 h incubation, the cells were trypsinized and centrifuged at 
1200 rpm for 5 min. Then, fluorescent dyes AO (0.5 μg/ml) and BE (10 μg/ml) were added to 
the cellular pellet. Freshly stained cell suspension was dropped on a glass slide and covered by 
a cover slip. Slides were observed with an Olympus BX41 fluorescence microscope equipped 
with a UV-mercury lamp (100W Ushio Olympus) and a U-N51004v2- FlTC/TRITC type filter 
set (FITC: BP480-495, DM500-545, BA515-535 and TRITC: BP550-570, DM575-, BA590-
621). Images were digitized on a computer through a video camera (Olympus digital camera 
XC50) and were analyzed with an image processor (Olympus cell^B Image Acquisition 
Software). The percentage of viable, apoptotic and necrotic cells was determined in at least 
100 cells. 
 
2.10. Cell cycle analysis by flow cytometry 
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 HeLa and MCF-7 tumor cells were cultured in 60 mm petri dishes for 24 h at a density 
of 5 x 104 or 1 x 105 cells/ml, respectively, and then treated with 1, 10 or 50 μg/ml of MTX-
CS-NPs or free MTX. After 24 h treatment, the cells were harvested by trypsinization, washed 
in cold PBS, fixed in ice-cold 70% ethanol and kept at -20ºC. Fixed cells were centrifuged, 
resuspended in DNA extraction buffer (0.2 M Na2PO4 and 0.1 M citric acid, pH 7.8) and 
incubated for 30 min at 37ºC. Then, the cells were stained with staining solution (20 μg/ml 
propidium iodide, 200 μg/ml RNAse A and Triton X-100 in PBS). The samples were kept in 
dark conditions for 1 h and measured with the Beckman Coulter ADC Epics XL flow 
cytometer (Beckman Coulter, FL, USA) (15,000 events were acquired for each sample). The 
data obtained were processed for cell cycle analysis with Multicycle® software. The amount of 
propidium iodide intercalating to DNA was used as the parameter to determine the cell cycle 
distribution phases.  
 
2.11. Lysosomal membrane integrity 
 Lysosomal membrane stability was assessed using the acridine orange (AO) relocation 
technique. AO is a lysosomotropic base (pKa = 10.3) that produces a red fluorescent emission 
when accumulated in acidic lysosomes. Disruption of the lysosomal membrane can be 
assessed by measuring the change in intracellular AO fluorescence (i.e., loss of the lysosomal 
red signal and gain of cytoplasmic green) [32]. HeLa and MCF-7 cells were exposed to MTX-
CS-NPs or free MTX (final concentrations of 1, 10 and 50 µg/ml) for 24 h. Then, the cells 
were trypsinized, centrifuged at 1200 rpm for 5 min, and 2 μg/ml AO was added to the cellular 
pellet. Freshly stained cell suspension was dropped on a glass slide and covered by a cover 
slip. Slides were observed on an Olympus BX41 fluorescent microscope, as described in 
Section 2.9.  
   
2.12. Hemocompatibility studies 
 12 
 Erythrocytes were isolated from rat blood, which was obtained from anesthetized 
animals by cardiac puncture and drawn into tubes containing EDTA. The procedure was 
approved by the institutional ethics committee on animal experimentation. The hemolysis 
assay was performed following the previously described procedure [17]. Twenty-five 
microliter aliquots of erythrocyte suspension were exposed to unloaded-CS-NPs at 
concentrations of 100, 250 and 500 μg/ml, and to MTX-CS-NPs or free MTX at 
concentrations of 10, 25 and 50 μg/ml. The samples were incubated at room temperature for 
10 minutes or 1 h. For the studies of erythrocyte agglutination, 10 μl of each sample was 
subjected to a hemolysis assay for 1 h (500 μg/ml of unloaded-CS-NPs and 50 μg/ml of MTX-
CS-NPS), placed on a glass slide, covered by a cover slip and analyzed by a phase contrast 
microscope (Olympus BX41, Olympus, Japan). 
 
2.13. pH-dependent membrane-lytic activity of nanoparticles 
2.13.1. Hemolysis assay as a model for the endosomal membrane 
 The pH-dependent membrane-lytic activity of the NPs was assessed using erythrocytes 
as a model of the endosomal membrane [33,34]. Increasing concentrations of unloaded-CS-
NPs and MTX-CS-NPs were added to erythrocytes suspended in PBS buffer of pH 7.4, 6.5 or 
5.4. The extent and kinetics of hemolysis were assessed as reported earlier [17]. 
 
2.13.2. Cell uptake studies - intracellular release of calcein  
 Calcein, a membrane-impermeant fluorophore, was used as a model drug molecule and 
tracer to monitor the stability of endosomes following vesicle uptake [35]. HeLa cells were 
plated (5 x 104 cells/ml) in 24-well plates on round cover glasses (Marlenfeld GmbH & 
Co.KG, Lauda-Könlgshofen, Germany) and incubated overnight at 37ºC under 5% CO2. Then, 
calcein (1 mg/ml) was added to the cells with or without (control cells) 250 or 500 μg/ml of 
unloaded-CS-NPs, or 25 or 50 μg/ml of MTX-CS-NPs in DMEM medium without FBS and 
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phenol red. After 1 h incubation at 37ºC, the cells were washed four times with PBS and 
incubated in complete medium for 3 h to allow intracellular trafficking. The cells were then 
washed with PBS and fixed with 4% (v/v) formaldehyde in PBS (pH 7.4) for 15 min at room 
temperature. Each individual cover glasses was mounted on clean glass slides with Prolong® 
Gold antifade reagent (Invitrogen) and analyzed on an Olympus BX41 fluorescence 
microscope equipped with a MNIBA3 filter set type (470-495 nm excitation, 510-550 nm 
emission and 505 nm dichromatic mirror). Images were digitized and analyzed as described in 
Section 2.9.  
  
2.14. Statistical analysis 
 All in vitro experiments were performed at least three times, using three replicate 
samples for each formulation concentration tested. The cytotoxicity of each formulation was 
expressed in terms of its IC50 (concentration causing 50% death of the cell population), 
calculated from concentration-response curves. Results are expressed as mean ± standard error 
of the mean (SE). Statistical analyses were performed using the Student’s t test or one-way 
analysis of variance (ANOVA) to determine the differences between the datasets, followed by 
Tukey’s or Dunnett’s post-hoc test for multiple comparisons using SPSS® software (SPSS 
Inc., Chicago, IL, USA). p < 0.05 and p < 0.005 were considered significant.  
 
3. Results  
3.1. Characterization of nanoparticles 
 Unloaded- and MTX-loaded NPs were characterized by DLS and TEM. Firstly, we 
assessed the effects of the dispersion medium (distilled water or culture medium), temperature 
and exposure time on NP hydrodynamic size. DLS measurements showed that fresh prepared 
(t = 0) unloaded-CS-NPs and MTX-CS-NPs dispersed in distilled water had an average 
hydrodynamic size of 350 nm and 301 nm, respectively (Table 2). After 24 h incubation (t = 
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24) at 37ºC, the NPs showed a slight size increase. In contrast, when the NPs were dispersed 
in the cell culture medium (DMEM with 5% FBS), the size increase was moderate by 0 h (579 
nm and 483 nm for unloaded-CS-NPs and MTX-CS-NPs, respectively), which indicates that 
NP agglomeration took place. After 24 h incubation under cell culture conditions, the 
unloaded-CS-NPs presented a bimodal size distribution, with particles smaller (108 nm) and 
larger (723 nm) than those obtained at t = 0. However, all the MTX-CS-NPs had a 
hydrodynamic size that was three times smaller (147 nm) after 24 h incubation in cell culture 
medium. PDI values below 0.3 were obtained in distilled water at both t = 0 and t = 24, which 
indicates that the NP population was relatively homogenous in size. In contrast, significantly 
higher PDI values (> 0.4) were found for the NPs dispersed in the cell culture medium. The 
NPs dispersed in water showed positive ZP values (~ 30 mV), whereas almost neutral values 
were obtained in cell culture medium.  
 A TEM analysis was also performed to assess NP morphology and size (Table 2). The 
results showed that at t = 0 both unloaded-CS-NPs and MTX-CS-NPs dispersed in water had a 
roughly spherical shape and were much smaller (~20-140 nm and ~20-60 nm, respectively) 
than the hydrodynamic size determined by DLS (350 and 301 nm, respectively). Finally, the 
entrapment efficiency achieved for NPs was found to be 63.41 ± 0.65% for MTX. This high 
incorporation capacity in the designed formulation is probably related to the chemical nature 
of the drug and to its interactions with the NP structure at the pH value of the experimental 
conditions. 
 
3.2. In vitro release study   
 The pH-dependent cumulative amount of MTX released from the MTX-CS-NPs is 
shown in Fig. 1. A control experiment using free MTX was also carried out under similar 
conditions and complete diffusion across the dialysis membrane was found to occur within 3 
h. The release of MTX from NPs at physiological pH showed an initial burst release of 18% 
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after 1 h, whereas about 75% and 100% was released after 8 h and 24 h, respectively. The 
initial MTX burst release at pH 6.5 was almost the same as at pH 7.4 (~18%), but greater 
release was achieved at each subsequent time point. In contrast, significantly faster (p < 0.05) 
drug release was obtained at pH 5.4: approximately 42% of the MTX was released from the 
NPs after 1 h, while total drug release was reached after only 6 h. 
 
3.3. In vitro cytotoxicity assessments 
3.3.1. Cell viability studies – antitumor activity 
 The MTT and NR dye interactions with NPs were studied to test the suitability of MTT 
and NRU viability assays for the cytotoxicity evaluation of CS-NPs. Our results showed slight 
interference of the NPs with the viability dyes. The NPs, especially the unloaded-CS-NPs, 
induced a slight increase in the MTT and NR absorbance values at 550 nm. These data were 
proved by the UV-vis measurements (data not shown). However, the interferences observed 
did not result in a further increase in cell viability with increasing NP concentration, which 
demonstrated that these interactions between NPs and viability dyes were not significant, and 
also proved that the viability endpoints are suitable for the intended purpose.  
 The cytotoxicity studies of unloaded-CS-NPs, MTX-CS-NPs and free MTX were 
performed using tumor (HeLa and MCF-7) and non-tumor (HaCaT) cell lines. Our results 
clearly proved that the activity of MTX-CS-NPs against the tumor cells was greater than that 
of the free drug (Fig. 2 and Table 3). The MTT and NRU endpoints showed moderate 
cytotoxic effects of free MTX (> 60% of viability), whereas MTX encapsulated in the NPs 
significantly reduced the cell growth by up to 17% and 33% of viability in HeLa and MCF-7 
cells, respectively (Fig. 2A). The MCF-7 cell line displayed higher resistance than the HeLa 
cells to both free MTX and MTX-CS-NPs. The non-tumor HaCaT cell line was much less 
sensitive to the antiproliferative and toxic effects of the MTX-CS-NPs (Fig. 2), with viabilities 
higher than 56% or 85% as measured by the MTT and NRU assays, respectively. Likewise, 
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the free MTX showed cytotoxicity to the HaCaT cells of less than 20%. Furthermore, the NPs 
affected cell viability in a time-dependent manner when they were added to the cells in the 
concentration range of 0.001-50 μg/ml for up to 48 h (Fig. 3A). The free MTX displayed 
similar cytotoxic behavior, but to a less significant extent. Table 3 shows the IC50 values 
(determined by the MTT assay) of the MTX-CS-NPs and free drug tested at 4, 24 and 48 h. 
Unloaded-CS-NPs showed low cytotoxic effects against all tested cell lines and displayed, in 
general, IC50 values > 500 μg/ml and at least 60% of cell viability (Table 3). Finally, as 
determined by the LDH assay, unloaded-CS-NPs, MTX-CS-NPs and free MTX did not affect 
the plasma membrane integrity of the three cell lines. Viability values above 90% were 
obtained in all the conditions tested. 
 Fig. 3B shows the effect of the medium’s pH during cell treatment on the cytotoxic 
responses of free MTX and MTX-CS-NPs in the tumor cell lines. Free MTX did not show any 
change in its cytotoxic activity on HeLa and MCF-7 cells when it was incubated under mildly 
acidic conditions (pH 6.6) for 4 and 24 h. In contrast, the higher concentrations of MTX-CS-
NPs displayed significantly higher cytotoxicity (p < 0.005) to both tumor cell lines after 4 h 
incubation at pH 6.6. The IC50 values decreased from > 50 to 21.86 μg/ml and > 50 to 33.09 
μg/ml in HeLa and MCF-7 cells, respectively. After 24 h incubation, the cytotoxic profile of 
the NPs was similar at both pH in HeLa cells, whereas in MCF-7 cells, the concentration of 10 
μg/ml showed significantly higher cytotoxicity at pH 6.6. The cytotoxic profile of unloaded-
CS-NPs did not change significantly when incubated at pH 6.6 (data not shown). 
  
3.3.2. Apoptosis 
 In order to determine whether the initial cell death observed in HeLa and MCF-7 tumor 
cells exposed to free MTX and MTX-CS-NPs could be due to apoptosis, AO/EB staining was 
carried out and the samples were analyzed under a fluorescence microscope. Fig. 4 reveals a 
significant increase (p < 0.05 or p < 0.005) in the number of apoptotic cells in both cell lines 
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following treatment with free MTX and MTX-CS-NPs. Furthermore, a greater increase in the 
fraction of apoptotic cells was induced by MTX-CS-NPs than by free MTX, especially in 
HeLa cells. The effects were dose-dependent for both MTX-CS-NPs and free MTX. The most 
significant effects were observed with the treatments that were also the most cytotoxic in all 
the viability assays. A slight to moderate increase was observed in the number of cells 
undergoing late apoptosis or necrosis, but these results did not differ significantly from those 
of the control cells. The untreated HeLa and MCF-7 cells were observed with a green intact 
nuclear structure (Fig. 4c and f, respectively), while after free MTX or MTX-CS-NP 
treatments we observed cells showing blebbing and nuclear margination (e.g. in Fig. 4d), 
chromatin condensation (e.g. in Fig. 4e) (early and moderate apoptosis), orange nuclei with 
normal chromatin distribution (necrosis) (e.g. in Fig. 4g), as well as apoptotic body separation 
and a reddish-orange color (late apoptosis) (e.g. in Fig. 4h). 
  
3.3.3. Cell cycle analysis 
 A flow cytometric analysis was performed to clarify the influence of MTX-CS-NPs on 
cell-cycle distribution in comparison with the free drug, and in addition to the cell viability 
studies. These experiments showed significant (p < 0.05 or p < 0.005) suppression of the 
G1/G0 and G2/M phases with cell cycle arrest in the S phase in both HeLa and MCF-7 cancer 
cells (Fig. 5). In HeLa cells, this effect was more pronounced after the free MTX treatment. In 
contrast, the MTX-CS-NPs induced greater accumulation of cells is the S phase in MCF-7 
after 24 h exposure. The distinct cell cycle arrest phase observed in cells treated with free 
MTX or MTX-CS-NPs might be due to the different consequences of unloaded or 
nanocarrier-loaded MTX in cancer cells. Moreover, a significant increase in the cell 
population was observed in the sub-G1 phase after treatment with MTX-CS-NPs, which is 
indicative of apoptotic cells. This corroborates the apoptosis experiments using AO/EB 
staining.  
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3.3.4. Lysosomal membrane integrity 
 The ability of free MTX and MTX-CS-NPs to induce lysosomal membrane 
permeabilization (LMP) was assessed using the AO relocation assay (Fig. 6). In control HeLa 
and MCF-7 cells, the lysosomes (red-orange granules) can be clearly seen as strong granular 
AO staining. MCF-7 cells treated with both MTX and MTX-CS-NPs showed little or no LMP 
by microscopic observation, whereas HeLa cells showed an increased LMP effect induced by 
50 µg/ml MTX-CS-NPs, as evidenced by the release of lysosomal contents into the cytoplasm 
(a reduction in red fluorescence).  
 
3.4. Hemocompatibility studies 
 The hemocompatibility of the NPs and free MTX was studied by hemolysis 
experiments (Fig. 7A). The release of hemoglobin was used to quantify their erythrocyte-
damaging properties. The unloaded-CS-NPs were non-hemolytic (less than 5%) after 10 min 
incubation and showed slight hemolysis after 1 h incubation (about 10% at the highest 
concentration). In contrast, MTX-CS-NPs at 50 μg/ml induced significantly higher hemolysis 
(> 70%) after both 10 and 60 min incubation. The free MTX was non-hemolytic in all the 
conditions. In addition, neither unloaded-CS-NPs nor MTX-CS-NPs induced agglutination of 
erythrocytes after 1 h of treatment with the lowest concentrations tested (100 and 250 μg/ml or 
10 and 25 μg/ml, respectively) (data not shown). In contrast, significant agglutination was 
induced by 500 μg/ml of unloaded-CS-NPs and 50 μg/ml of MTX-CS-NPs (Fig. 7B).  
 
3.5. pH-dependent membrane-lytic activity of nanoparticles 
3.5.1. Hemolysis assay as a model for the endosomal membrane 
 Fig. 8A shows the membrane-lytic activity of the NPs as a function of concentration 
with varying pH and incubation time. Negligible membrane lysis was induced by unloaded-
CS-NPs after 10 min incubation at physiological pH, while 60 min incubation prompted at 
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most 11% of hemolysis. Interestingly, MTX-CS-NPs at 50 μg/ml induced 70.5% and 94.5% 
of membrane lysis after 10 and 60 min incubation, respectively. As the pH decreased to 6.5 or 
5.4, the membrane-lytic activity of the unloaded-CS-NPs increased significantly (p < 0.05) in 
a dose-dependent manner. The unloaded-CS-NPs reached a maximum hemolysis of 61.2% 
and 83.5% after 60 min of incubation at pH 6.5 and 5.4, and were 5.5- and 7.6-fold more 
hemolytic than at pH 7.4, respectively. MTX-CS-NPs showed higher membrane lysis in an 
acidic environment and were also more active than the unloaded-CS-NPs. MTX-CS-NPs at 25 
μg/ml already induced 12.9% and 43.4% of hemolysis after 60 min incubation at pH 6.5 and 
5.4, respectively, and were 4.8- and 16.1-fold more hemolytic than at pH 7.4. At 50 μg/ml, the 
membrane-lytic activity did not differ significantly from that at pH 7.4. Finally, unloaded-CS-
NPs without 77KL were prepared to prove that the pH-sensitive membrane-lytic activity of 
the NPs could be attributed to the surfactant. These NPs showed at most 3.8%, 11.6% and 
15.5% of hemolysis at pH 7.4, 6.5 and 5.4, respectively. The hemolysis of free MTX was also 
assessed at pH 7.4, 6.5 and 5.4, but no membrane lysis was obtained in any of the conditions 
(data not shown). 
   
3.5.2. Calcein uptake and endosomal stability 
 The ability of the NPs to release endocytosed materials into the cell cytoplasm was 
examined by fluorescence microscopy, following the uptake of calcein and NPs into HeLa 
cells. As shown in Fig. 8B, cells treated with calcein alone (control cells) showed a bright 
punctate distribution of fluorescence, which is consistent with constitutive endocytosis of the 
external medium. When the cells were co-incubated with calcein and unloaded-CS-NPs or 
MTX-CS-NPs, diffuse green fluorescence staining was observed in the cytoplasm, which 
indicates destabilization of the endosomal membrane and release of calcein to the cell cytosol. 
These results corroborated the hemolysis experiments, in which the NPs showed increased 
membrane-lytic activity in the pH range characteristic of endosomal compartments.  
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4. Discussion 
 The ionic gelation method was chosen to form the NPs because of the ability of CS to 
gel spontaneously on contact with multivalent polyanions. To form ionic crosslinks with TPP 
and 77KL, the pH of CS solution was set at 5.5, because at this pH the formation of smaller 
NPs with higher ZP value was reported [7]. In addition, at pH 5.5, about 90% of the amino 
groups of CS (pKa = 6.5) are protonated [36], which ensures that the crosslinking process 
takes place to form CS-TPP-NPs. Finally, a pH value of 5.5 would ionize ~50% of the 
carboxylic groups of MTX (pKa = 4.8 and 5.5), which allows attractive electrostatic 
interactions between the negatively charged drug molecules and positively charged CS 
molecules [6]. Therefore, during the process of incorporating the drug into the NPs, we can 
assume that the MTX molecules are both adsorbed at the particle surface [37] and 
entrapped/embedded in the CS nano-matrix by hydrogen bonding and hydrophobic forces [6].  
 The NP hydrodynamic size characterization in water using DLS showed that only a 
small increase in mean diameter was observed after 24 h, which means that the incubation 
time and temperature of the cell culture experiments did not directly affect the stability of the 
NPs, and that the dispersion medium plays a key role in their aggregation behavior. When 
dispersed in cell culture medium and maintained in the conditions of the cytotoxicity assays, 
both unloaded-CS-NPs and MTX-CS-NPs displayed unexpected behavior. The increase in 
measured particle size at t = 0 in protein-containing medium may be due to protein coating of 
the particles and aggregation [7,28]. At the pH of the cell culture medium (~ 7.4), there is a 
considerable reduction in the degree of protonation at the NPs surface (confirmed by the ZP 
values), which decreases electrostatic repulsion between the particles and, thereby, increases 
the probability of particle aggregation. However, the decreasing protonation state of the CS 
molecule in the particle surface might lead to desorption of the superficial molecules, due to 
reduced ionic interaction with both TPP and 77KL. This process probably has a slow 
equilibration, which may justify the shaping of smaller NPs after 24 h incubation in the cell 
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culture medium. The MTX-CS-NPs showed a slight reduction in the ZP value that may be due 
to the decreased number of free positive groups of CS in the NP surface, which 
electrostatically attached to the MTX molecules. The TEM experiments displayed NPs with a 
much smaller diameter than the hydrodynamic size measured by DLS, which could be due to 
the resolution limitation of DLS [38], to the swelling of the NPs in the presence of water [4] or 
even to the fact that DLS gives the mean hydrodynamic diameter of the particle core 
surrounded by the solvation layers, whereas TEM gives the diameter of the particles alone in 
the dry state [39]. NPs loaded with MTX were even smaller than unloaded-CS-NPs (as also 
demonstrated by DLS), which suggests that the drug increased the degree of NP compaction. 
Moreover, in the TEM images we can see some other material that is not condensed in the 
structure of the NPs, which might be unreacted polymer chains that are not involved in NP 
formation. 
  It was shown that the cumulative release rates of MTX from NPs were effectively 
slower than those of the free drug solution. The observed initial burst release of MTX from the 
NPs might be due to drug molecules that were loosely incorporated into them, e.g., by 
electrostatic interaction between the positively charged amino groups of CS in the particle 
surface and the ionized carboxyl groups of MTX. At physiological pH, we obtained a 
relatively slow release up to 24 h, which could be attributed to drug diffusion and the 
swelling/degradation of the polymer [40]. In contrast, the release rate was accelerated by 
decreasing pH, which confirms the pH-dependent release pattern of this nanoarchitecture. The 
slightly increased release at pH 6.5 might mean that anticancer drug delivery is triggered at 
tumor extracellular pHe (a pH range from 6.5 to 7.2) [23] or early endosomal compartment. 
Moreover, the MTX release from NPs was significantly increased at pH 5.4, which supports 
the idea of effectively increased intracellular drug delivery through the late endosomes. The 
triggered release of payload under acidic conditions might be attributed to the pH-dependent 
activity of 77KL [17]. The ionization of 77KL (pKa = 6.2) tends to decrease under acidic 
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conditions, which might contribute to destabilizing the NP structure, due to the reduced 
amount of available anionic groups that interact electrostatically with the positive amino 
groups of CS. Finally, high release in an acidic environment might be favored by the lower 
degree of MTX ionization under this condition, which would decrease the electrostatic 
interaction of the drug with the positively charged NP surface.The development of a switching 
carrier in release kinetics, from slow release while circulating to rapid release kinetics once 
target sites have been reached, is of great importance to avoid the multidrug resistance (MDR) 
of initially sensitive tumor cells caused by slow release at the site of action [23].    
 In vitro model systems provide a rapid and effective means to assess NPs for a number 
of toxicological endpoints and mechanism-driven responses. Here, we showed the relative 
selectivity of the NPs for cancer cells, as the cytotoxic effects of MTX-CS-NPs were 
significantly lower in the non-tumor control cells (HaCaT). These findings might be related to 
distinct cell uptake depending on the cell nature or cell proliferative status. Moreover, we 
clearly showed that the MTX-CS-NPs had greater antitumor effects in vitro against the cancer 
cells than the free MTX. The low antiproliferative effect of the native drug obtained in our 
study is very well correlated with the duration of its intracellular retention. Free MTX is found 
to be pumped off the cell cytosol by P-glycoprotein, which participates in the development of 
resistance to antifolates [41]. Moreover, the availability of free MTX at its intracellular site of 
action depends on a passive diffusion mechanism, which can be limited by the high ionization 
state of MTX at physiological pH. In contrast, the obviously enhanced cytotoxicity of MTX 
via the nano-sized particles means that there was a significant reverse effect of drug 
resistance. NPs could reduce the MDR that characterizes many anticancer drugs by a 
mechanism of cell internalization of the drug by endocytosis [42], by lowering drug efflux 
from the cells [43] and/or by allowing pH-dependent drug release from the endosomes to cell 
cytosol [44]. As demonstrated in Section 3.5, the pH-sensitivity of NPs allowed their rapid 
escape from the endosomal compartment, which may enhance their therapeutic efficiency 
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compared to the native drug. MTT was the most sensitive viability assay for detecting the 
cytotoxic effects of the NPs, regardless of the cell line. This implies that although NPs 
primarily exerted toxicity on the mitochondrial compartment after cellular internalization, the 
plasma membrane remained intact. This finding could be related to the mechanism of action 
of MTX. MTX is a potent inhibitor of the enzyme dihydrofolate reductase, which plays a key 
role in the synthesis of DNA precursors and cell growth [10]. Therefore, MTX is a 
chemotherapeutic agent that mainly inhibits cell proliferation, which justifies the lack of LDH 
release to the cell cytosol due to membrane rupture (late stage of cell death). We also showed 
that unloaded-CS-NPs reduced cell viability, especially in HeLa cells. This is most likely due 
to the combined effect of the free amines of the polymer at the NP surface and the cytotoxic 
potential of the surfactant by itself. Finally, although our overall results were in line with a 
previous report [10] and showed that MCF-7 cells displayed resistance to MTX, we also 
proved the greater activity of MTX-CS-NPs against this cell line. 
 The cytotoxic activity of pH-sensitive NPs was also investigated to test their feasibility 
in targeting acidic tumor extracellular pHe. Although free MTX had no enhanced effect in an 
acidic environment, the MTX loaded into the NPs showed pronounced cytotoxicity at low pH, 
which might be attributed to the accelerated release of MTX triggered by pH. Moreover, the 
increased cytotoxicity at pH 6.6 may be due to the combined effect of increased protonation of 
77KL and CS groups on the NP surface at tumor pH, which increases binding to the cell 
membrane, leading to greater internalization and, thus, greater NP cytotoxicity. These findings 
support the idea that the MTX-CS-NPs truly discriminate the small difference between the 
physiological and tumor pHe by destabilization and the release rate [23].  
 After we had shown that MTX-CS-NPs exerted cytotoxic effects on the proliferation of 
cancer cells in a typically dose-dependent manner, we examined whether the induction of 
apoptosis, LMP or alterations in the normal cell cycle were the possible molecular 
mechanisms involved in the antitumor activity of NPs in comparison to the free drug. 
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Although the treatment of cancer cells with free MTX significantly inhibited the cell cycle in 
the S-phase, these cells were essentially more resistant to free MTX-induced apoptosis. In 
contrast, MTX-CS-NPs induced more significant signs of apoptosis, increased the reduction in 
cell proliferation and also arrested the cell cycle in the S-phase. Altogether, these data 
indicated that free MTX acted mainly as a cytostatic drug on HeLa and MCF-7 cancer cells, 
suppressing DNA synthesis and cellular growth, whereas the MTX loaded into CS-NPs 
induced both cytostatic and cytotoxic effects [45,46]. Finally, we showed that the LMP effect 
participated slightly in the mechanism involved in MTX-CS-NPs toxicity in HeLa cells, but 
not in MCF-7 cells. The LMP induced in HeLa cells by high concentrations of NPs suggests 
that the lysosomal damage might play some role in the resulting apoptotic effects of MTX-CS-
NPs. It was reported that the LMP effect leads to the translocation of lysosomal hydrolases to 
the rest of the cell, which frequently mediates apoptosis by inducing mitochondrial structural 
dysfunction [46]. These results indicated that the damage of lisosomal integrity and the early 
mitochondrial injury (corroborated by the higher sensitivity of MTT assay for detecting NP 
cytotoxicity) might also support the greater susceptibility of HeLa cells to the toxic effects of 
MTX. 
 The assessment of the hemocompatibility of a nanocarrier is indispensable for frequent 
intravenous dosing. The incorporation of MTX into the NPs was found to increase their 
hemolytic potential. However, when tested under the same conditions as the NP formulations, 
free MTX did not induce any undesirable response. Therefore, the main source of hemolysis 
might be the effects that the drug moiety produces on the NP surface or when encapsulated on 
it. Indeed, it was recently reported that MTX incorporated in liposomal formulations displayed 
higher hemoreactivity than its free solution [47]. The agglutination induced by the NPs at the 
highest concentration tested may be caused by increased binding of the NPs to the erythrocyte 
membrane, which might deformed cells and hence decrease the repulsion among them [48].  
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 In our previous study [17], we showed the high efficiency of the amphiphile 77KL at 
disrupting cell membranes within the pH range characteristic of late endosomes. Therefore, 
the rationale behind assessing the membrane-lytic behavior of the NPs was to establish the 
ability of NPs containing this amphiphile to promote triggered release of entrapped molecules 
in a pH-dependent fashion. The enhanced hemolysis induced by NPs at acidic pH might be 
due to the increasing protonation state of the carboxylic group of 77KL in this condition. The 
protonation of the 77KL molecule makes it non-ionic and enhances its hydrophobicity, which 
would increase binding to the membrane and, thus, its lysis. The rather unexpected greater 
membrane-lytic activity of MTX-CS-NPs could be attributed to a competitive effect between 
MTX and 77KL molecules for binding to the positive NP surface. Both structures were 
negative charged and, thus, MTX molecules could induce faster release of 77KL molecules 
from the NP surface, which would result in increased hemolysis. 
 The membrane-lytic activity of the NPs in an acidic environment might facilitate 
escape from the endocytotic pathway to lysosomes, and allow efficient intracellular drug 
delivery to the cell cytosol. To corroborate this pH-sensitive activity of the NPs at intracellular 
level, we used calcein as an endosomal tracer molecule, which is internalized by the cell 
through endocytosis and is used to monitor the stability of endosomes following NP uptake 
[35]. In the absence of NPs, endososomal compartmentalization of calcein was observed, 
which indicates that the endosome membranes were not damaged [35]. In contrast, the CS-
NPs induced efficient release of endocytosed material into the cytoplasm. On the basis of 
these experiments, we conclude that the NPs deliver calcein to the cytosol of cells by co-
endocytosis of this dye and NPs, followed by NP-induced disruption of endosomes and escape 
of the dye into the cytosol. The cellular uptake of CS-NPs seems to occur by adsorptive 
endocytosis, as the uptake of similar NPs was previously reported to occur predominantly by 
adsorptive endocytosis in A549 cells [49] as well as in the HeLa cell line [15].  
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5. Conclusions 
 In this study, MTX-loaded CS-NPs have been successfully formulated as an 
intracellular delivery system for improved antitumor activity. The inclusion of the surfactant 
77KL on the NP formulations clearly gives them pH-sensitive membrane-lytic behavior. This 
facilitates cytosolic delivery of the fluorescent endosomal tracer calcein, and consequently of 
the encapsulated drug, through endosomal membrane lysis. Furthermore, the NPs showed high 
encapsulation efficiency, accelerated release of MTX at a decreasing pH from 7.4 to 5.4, 
acceptable hemocompatibility and enhanced cytotoxicity on HeLa and MCF-7 tumor cell lines 
in comparison to free MTX. Another advantage of MTX-CS-NPs was found to be their greater 
cytotoxic activity around tumor extracellular pHe compared to that at physiological pH. The 
combination of the physicochemical characteristics and pH-sensitivity of the NPs resulted in 
superior cytotoxicity of the entrapped drug, together with generally greater cell cycle arrest 
and a higher apoptotic response. Based on the overall results, the combined mechanisms of 
pH-triggered release and cytotoxicity, together with the specific ability to lyse the endosomal 
membrane after cell internalization, makes MTX-CS-NPs containing the lysine-based 
surfactant 77KL a beneficial approach that provides increased anticancer efficacy at the tumor 
site. However, further in vivo studies must be conducted in this field to prove the hypothesis. 
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Figure captions: 
 
Fig. 1. pH-dependent in vitro cumulative release of MTX from NPs in PBS buffer at pH 7.4, 6.5 and 5.4. Results 
are expressed as the mean ± SE of three independent experiments. Statistical analyses were performed using 
ANOVA followed by Tukey’s multiple comparison test. a Significantly different from PBS pH 7.4 (p < 0.05) and b 
significantly different from PBS pH 6.5 (p < 0.05). 
Fig. 2. The effect of MTX-CS-NPs or free MTX concentration and viability assay (MTT and NRU) on the survival 
rates of (a) HaCaT, (b) HeLa and (c) MCF-7 cell lines. Data are expressed as the mean of three independent 
experiments ± SE. Statistical analyses were performed using ANOVA followed by Tukey’s multiple comparison 
test. a Significantly different from HaCaT cells (p < 0.05) and b significantly different from MCF-7 cells (p < 0.05). * 
p < 0.05 and ** p < 0.005 denote significant differences from free MTX. 
Fig. 3. Cytotoxicity of MTX-CS-NPs and free MTX on HeLa and MCF-7 tumor cell lines. (A) Time-dependent 
cytotoxicity of MTX-CS-NPs and free MTX at the 0.001-50 μg/ml concentration range in tumor HeLa and MCF-7 
cells, as determined by a MTT assay. (B) pH-dependent cytotoxicity of MTX-CS-NPs and free MTX against HeLa 
and MCF-7 cells after 4 and 24 h incubation, as determined by a MTT assay. Data are expressed as the mean of 
three independent experiments ± SE. Statistical analyses were performed using ANOVA followed by Tukey’s 
multiple comparison test. * p < 0.05 and ** p < 0.005 denote significant differences from the cytotoxic effects at pH 
7.4. 
Fig. 4. Effect of MTX-CS-NPs and free MTX on apoptosis of (a) HeLa cells and (b) MCF-7 cells determined by 
fluorescence microscopy after AO/BE staining. Results are expressed as the percentage of viable, apoptotic and 
necrotic cells after 24 h treatment with 1, 10 or 50 μg/ml of MTX-CS-NPs or free MTX. Fluorescent micrographs of 
HeLa cells: (c) untreated control cells, (d) 50 μg/ml free MTX, (e) 50 μg/ml MTX-CS-NPs and of MCF-7 cells: (f) 
untreated control cells, (g) 50 μg/ml free MTX, (h) 50 μg/ml MTX-CS-NPs. Legends: (►) typical live nuclei, (▼) 
chromatin condensation (early apoptosis), (▲) blebbing and nuclear margination (early to moderate apoptosis), (*) 
necrosis, (**) late apoptosis. Statistical analyses were performed using ANOVA followed by Dunnett’s or Tukey’s 
multiple comparison test. * p < 0.05 and ** p < 0.005 denote significant differences from untreated control cells. a 
Significantly different from free MTX (p < 0.05). 
Fig. 5. Cell-cycle analysis of (a) HeLa and (b) MCF-7 cells following 24 h treatment with 1, 10 or 50 μg/ml of MTX-
CS-NPs or free MTX. Results are expressed as the mean ± SE of three independent experiments, performed in 
duplicate. Statistical analyses were performed using ANOVA followed by Dunnett’s or Tukey’s multiple 
comparison test. * p < 0.05, ** p < 0.005 denote significant differences from untreated control cells. a Significantly 
different from free MTX (p < 0.05). 
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Fig. 6. Assessment of MTX-CS-NPs and free MTX effects on lysosomal membrane permeabilization (LMP) in 
HeLa and MCF-7 cells as visualized via AO staining. In untreated control cells, lysosomes can be seen as red-
orange granules and cytoplasm has a diffuse green fluorescence. In cells with lysosomal membrane damage 
(HeLa cells treated with 50 μg/ml MTX-CS-NPs), lysosomes exhibit a shift from red-orange to a yellow-green 
fluorescent color.  
Fig. 7. Hemocompatibility of unloaded-CS-NPs and MTX-CS-NPs. (A) Percentage of hemolysis caused by NPs 
after 10 and 60 min of incubation with rat erythrocytes. Each value represents the mean ± SE of three 
experiments. (B) Agglutination of rat erythrocytes observed by phase microscopy after 1h of incubation with 500 
μg/ml of NPs. 
Fig. 8. (A) pH-sensitive membrane-lytic activity of unloaded-CS-NPs (with or without 77KL) and MTX-CS-NPs. 
NP-induced hemoglobin release from rat erythrocytes was expressed as a function of pH, concentration and 
incubation time. Results are expressed as the mean ± SE of three independent experiments. Statistical analyses 
were performed using ANOVA followed by Tukey’s multiple comparison test. a Significantly different from pH 7.4 (p 
< 0.05) and b significantly different from pH 6.5 (p < 0.05). (B) Fluorescence microscopy images of HeLa cells 
showing the subcellular distribution of calcein fluorescence. The cells were treated with 1 mg/ml calcein (control); 
both 1 mg/ml calcein and 250 or 500 μg/ml of unloaded-CS-NPs or 25 or 50 μg/ml of MTX-CS-NPs. Images were 
acquired at 3 h after 1 h of uptake.  
 
  
 
 
 
Table 1. Physicochemical properties of the anionic lysine-based surfactant 77KL. 
 
Chemical structure Molecular weight  
405.6 g/mol 
 
Critical micellar 
concentration (CMC) 
 
2.9 x 103 μg/ml 
pKa 
 
6.2 
Number of alkyl chains 
 
2 
Length of alkyl chain 
 
C8 
 
Li+ 
Table 2. Characterization properties of the nanoparticles.  
 Unloaded-CS-NPs MTX-CS-NPs 
 Hydrodynamic size (nm) ± SE a 
t = 0 h water 350.47 ± 13.31  301.17 ± 8.96  
t = 0 h DMEM 5% FBS 579.40 ± 18.71/ 17.39 ± 0.45 c 483.50 ± 45.03/ 14.80 ± 0.78 c  
t = 24 h water b 403.53 ± 13.23  312.57 ± 9.71  
t = 24 h DMEM 5% FBS b 108.41 ± 14.42/ 723.15 ± 32.15 c 147.73 ± 1.83  
 PDI ± SE a 
t = 0 h water 0.269 ± 0.009  0.257 ± 0.008  
t = 0 h DMEM 5% FBS 1.00 ± 0.001  0.680 ± 0.011  
t = 24 h water b 0.260 ± 0.018 0.269 ± 0.005  
t = 24 h DMEM 5% FBS b 0.517 ± 0.087  0.431 ± 0.029  
 ZP (mV) ± SE a 
t = 0 h water 30.07 ± 1.18  26.87 ± 0.90  
t = 0 h DMEM 5% FBS -4.41 ± 0.35  -4.74 ± 0.29 
 TEM diameter (nm) 
t = 0 h water 20 - 140 20 - 60 
TEM images d 
  
a Mean of three experiments ± SE. 
b Incubated under cell culture conditions: 37ºC, 5% CO2. 
c Predominanting size is indicated first.  
d Scale bars = 200 nm 
Table 3. Cytotoxicity expressed as IC50 values of free MTX, unloaded-CS-NPs and MTX-
loaded-CS-NPs in HeLa, MCF-7 and HaCaT cell lines. 
Cytotoxicity assay – 24 h treatment - IC50 ± SE (μg/ml)  
Cell line MTT NRU LDH 
Free MTX 
HeLa > 50  > 50  > 50  
MCF-7 > 50 > 50 > 50 
HaCaT > 50 > 50 > 50 
MTX-CS-NPs 
HeLa 4.37 ± 0.37 17.69 ± 0.14 > 50  
MCF-7 34.72 ± 6.23 35.35 ± 5.38 > 50 
HaCaT > 50 > 50 > 50 
Unloaded-CS-NPs 
HeLa 260.39 ± 54.32 > 500 > 500 
MCF-7 > 500 > 500 > 500 
HaCaT > 500 > 500 > 500 
Time-dependent antitumoral activity - IC50  ± SE (μg/ml) – MTT assay 
pH 7.4 
 4 h 24 h 48 h 
Free MTX 
HeLa > 50 > 50 0.0089 ± 0.12 
MCF-7 > 50 > 50 19.13 ± 2.37 
MTX-CS-NPs 
HeLa 42.93 ± 2.37 4.37 ± 0.37 0.0098 ± 0.05 
MCF-7 > 50 34.72 ± 6.23 8.76 ± 1.07 
pH 6.6 
Free MTX 
HeLa > 50 > 50 - 
MCF-7 > 50 > 50 - 
MTX-CS-NPs 
HeLa 21.86 ± 1.98 6.76 ± 2.54 - 
MCF-7 33.09 ± 2.31 28.97 ± 1,74 - 
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